SCHEDULE: Avoro Capital Advisors Cuts Soleno Therapeutics Stake

Avoro Capital Advisors and Behzad Aghazadeh have reduced their beneficial ownership in Soleno Therapeutics to 4.1%, as disclosed in an amended Schedule 13G filing.

Summary

• Avoro Capital Advisors LLC and its controlling person, Behzad Aghazadeh, have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Soleno Therapeutics Inc.
• The reporting persons collectively beneficially own 2,050,000 shares of Soleno Therapeutics Common Stock.
• This represents 4.1% of the company's outstanding Common Stock.
• The percentage is calculated based on 50,393,931 shares of Common Stock outstanding as of May 2, 2025, as reported in Soleno Therapeutics' Form 10-Q filed on May 7, 2025.
• Avoro Capital Advisors LLC is a Delaware limited liability company providing investment advisory and management services, holding shares for investment purposes on behalf of Avoro Life Sciences Fund LLC.
• Behzad Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors LLC.
• The acquisition of these securities was for investment purposes in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in a significant institutional stake, which can be interpreted as a loss of conviction or a strategic shift by the investor. However, the investor still retains a notable position, preventing a strongly negative score.

Positives

• A significant institutional investor, Avoro Capital Advisors, continues to hold a substantial stake of 4.1% in Soleno Therapeutics, indicating continued, albeit reduced, interest in the company.

Negatives

• The reduction in beneficial ownership from a previous stake of 5% or more to 4.1% by Avoro Capital Advisors and Behzad Aghazadeh could signal a decrease in investor conviction or a strategic reallocation of capital.

Risks

• A reduction in a significant institutional investor's stake may lead to negative market perception and potential downward pressure on the stock price.
• The filing does not provide specific reasons for the reduction in ownership, leaving room for speculation regarding the investor's outlook on the company's future performance.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Soleno Therapeutics' future performance or strategic direction.

Industry Context

This filing reflects a change in institutional ownership within the biotechnology or pharmaceutical sector, where investor confidence and strategic positioning by major funds can significantly influence company valuation and market sentiment.

Stakeholder Impact

• Shareholders: The reduction in a significant institutional stake may lead to decreased investor confidence and potential downward pressure on the share price.
• Investment Professionals: Provides insight into the portfolio adjustments of a notable investment advisor, which may influence their own investment decisions regarding Soleno Therapeutics.

Key Dates

Recommendation

The filing indicates a reduction in beneficial ownership by a significant institutional investor, Avoro Capital Advisors, to 4.1%. While this suggests a potential decrease in conviction or portfolio rebalancing, the investor still retains a notable stake. Without further information on the reasons for the reduction or the company's underlying fundamentals, a 'hold' recommendation is prudent, advising investors to monitor future disclosures and company performance.

Keywords

Soleno Therapeutics, Avoro Capital Advisors, Behzad Aghazadeh, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, SEC Filing